Virax Biolabs Group Ltd (VRAX) stock
VRAXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends March 31
$0.45−0.00 (-0.65%)
Close on Nov 17, 2026Market cap $257.81KP/E –Yield –
Virax Biolabs r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2026 it was $3.74M, up 84.0% from the year before. The highest annual figure on record is $3.74M in fiscal 2026.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | $3.74M | +84.0% |
| FY2025 | Mar 31, 2025 | $2.03M | +25.8% |
| FY2024 | Mar 31, 2024 | $1.61M | -25.9% |
| FY2023 | Mar 31, 2023 | $2.18M | +402.4% |
| FY2022 | Mar 31, 2022 | $433.74K | +260.8% |
| FY2021 | Mar 31, 2021 | $120.22K | – |
See a number that looks wrong?